Amgen Inc. (AMGN)
After hours:
| Previous close | 276.38 |
| Open | 276.04 |
| Bid | 273.90 x 100 |
| Ask | 274.19 x 100 |
| Day's range | 272.35 - 276.11 |
| 52-week range | 211.71 - 329.72 |
| Volume | |
| Avg. volume | 2,926,600 |
| Market cap | 146.935B |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | 21.92 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 9.00 (3.28%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
- Zacks
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
- Reuters
Sandoz reaches agreement with Amgen over patent dispute
Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars. The agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances, Sandoz said in a statement. "The terms of the agreement will not impact our previously disclosed 2024 guidance," Sandoz said.
- Zacks
What's in the Cards for Amgen (AMGN) This Earnings Season?
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
